Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126885012 | 12688501 | 2 | F | 20160527 | 20160913 | 20160826 | 20160921 | EXP | US-009507513-1608USA010584 | MERCK | 50.00 | YR | M | Y | 67.57000 | KG | 20160921 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126885012 | 12688501 | 1 | PS | ZEPATIER | ELBASVIRGRAZOPREVIR | 1 | Oral | 1 TABLET ONCE A DAY | 208261 | 1 | DF | TABLET | QD | ||||||
| 126885012 | 12688501 | 2 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | UNK | 0 | |||||||||||
| 126885012 | 12688501 | 3 | C | ASPIRIN. | ASPIRIN | 1 | 0 | ||||||||||||
| 126885012 | 12688501 | 4 | C | BUSPIRONE HYDROCHLORIDE. | BUSPIRONE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126885012 | 12688501 | 5 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | 0 | ||||||||||||
| 126885012 | 12688501 | 6 | C | DOXEPIN HYDROCHLORIDE. | DOXEPIN HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126885012 | 12688501 | 7 | C | LASIX | FUROSEMIDE | 1 | 0 | ||||||||||||
| 126885012 | 12688501 | 8 | C | ATARAX | HYDROXYZINEHYDROXYZINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126885012 | 12688501 | 9 | C | IMDUR | ISOSORBIDE MONONITRATE | 1 | Oral | 0 | PROLONGED-RELEASE TABLET | ||||||||||
| 126885012 | 12688501 | 10 | C | TOPROL XL | METOPROLOL SUCCINATE | 1 | 0 | ||||||||||||
| 126885012 | 12688501 | 11 | C | NITRO-DUR | NITROGLYCERIN | 1 | Transdermal | UNK | 0 | TRANSDERMAL PATCH | |||||||||
| 126885012 | 12688501 | 12 | C | REQUIP | ROPINIROLE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126885012 | 12688501 | 13 | C | TRAZODONE HYDROCHLORIDE. | TRAZODONE HYDROCHLORIDE | 1 | Oral | 100 MG, NIGHT | 0 | 100 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126885012 | 12688501 | 1 | Hepatitis C |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126885012 | 12688501 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126885012 | 12688501 | Blood creatine phosphokinase increased | |
| 126885012 | 12688501 | Myalgia | |
| 126885012 | 12688501 | Type 2 diabetes mellitus |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126885012 | 12688501 | 1 | 20160527 | 20160818 | 0 | |
| 126885012 | 12688501 | 2 | 2016 | 0 |